Recently, the vaccine giant Chongqing Zhifei Biological Products Co.Ltd(300122) released the annual report of 2021 and the first quarterly report of 2022.
In the latest list of the top ten circulating shareholders in the first quarterly report, a private placement company called Yingshui investment made a lot of money, and its two products appeared. Among them, the total stock market value at the end of the period reached 2.994 billion yuan.
As a major player in the science and innovation board, Yingshui investment’s products have attracted much attention because they have been included in the “blacklist” of stock placement for two times. In 2020, Yingshui investment madly launched hundreds of products, and the scale exceeded the 10 billion mark in July of that year.
In 2021, Yingshui investment made a huge profit of 2 billion yuan with nearly 400 products, ranking first in the whole private placement industry. However, with the frequent breaking of new shares this year, Yingshui investment, which relies on the new strategy, will also usher in the performance test.
It is worth noting that the Chinese reporter of the securities firm found that the performance of Yingshui investment’s products is seriously differentiated. Some of its products have achieved positive returns this year, some products are near the profit and loss, but many products have floating losses of more than 20%, and the net value of some products is even lower than 0.8.
Some industry insiders said that the performance of private placement products varies greatly, which may make it difficult for investors to judge their real investment level, and the experience held by different customers will also vary greatly.
hit new big investors and made a huge investment of 3 billion yuan Chongqing Zhifei Biological Products Co.Ltd(300122)
Yingshui investment is a private placement company founded in 2015. The competent team includes Lu Gaowen (once worked in CICC and Shanghai Tuofeng Trading Co., Ltd.), Yao Jiejun (once worked in the financial management department of China The Pacific Securities Co.Ltd(601099) insurance group and Ruoyu investment, and is currently responsible for the research of pharmaceutical and chemical industry).
In the past quarter, Yingshui invested heavily in building positions Chongqing Zhifei Biological Products Co.Ltd(300122) . Among them, Yingshui Heli No. 13 and Yingshui Heli No. 9 held 11.717 million shares and 9.966 million shares respectively, with a total number of 21.68 million shares. The market value of the shares at the end of the period was 1.617 billion yuan and 1.375 billion yuan respectively, with a total stock market value of 2.994 billion yuan.
Chongqing Zhifei Biological Products Co.Ltd(300122) 2021 financial report shows that last year, the revenue reached 30.652 billion yuan, a year-on-year increase of 101.79%; The net profit attributable to the parent company was 10.209 billion yuan, a year-on-year increase of 209.23%. As the exclusive agent of MSD HPV vaccine in Chinese Mainland, the annual batch issuance volume of Chongqing Zhifei Biological Products Co.Ltd(300122) 9-valent and 4-valent HPV vaccines was 102062 million and 8.8025 million respectively, with a year-on-year increase of 101.45% and 21.93%.
In the first quarter of 2022, Chongqing Zhifei Biological Products Co.Ltd(300122) ‘s performance continued to grow significantly. The total operating revenue was 8.84 billion, a year-on-year increase of 125.2%; The net profit attributable to the parent company was 1.92 billion, a year-on-year increase of 105%.
However, it should be noted that the operating cost of Chongqing Zhifei Biological Products Co.Ltd(300122) in the first quarter of 2022 was 5.86 billion, a year-on-year increase of 152.9%, higher than the growth rate of 125.2% of operating revenue, resulting in a decrease of 7.3% in gross profit margin. Operating cash flow decreased significantly by 2814.4% to -3.32 billion.
Although the performance is brilliant, this year’s Chongqing Zhifei Biological Products Co.Ltd(300122) is not smooth.
On April 14, a news that “who suggested that one shot of HPV vaccine is enough” aroused market attention, and the logic of Chongqing Zhifei Biological Products Co.Ltd(300122) being hyped by the market is the exclusive agent of methadone HPV vaccine. Affected by this, the share price of Chongqing Zhifei Biological Products Co.Ltd(300122) plunged 14.19% to 116 yuan.
Subsequently, the share price of Chongqing Zhifei Biological Products Co.Ltd(300122) fell below the 100 yuan mark from 116 yuan. As of Friday’s closing, Chongqing Zhifei Biological Products Co.Ltd(300122) reported 94.5 yuan, down more than 24% during the year.
This time, Yingshui investment bought Chongqing Zhifei Biological Products Co.Ltd(300122) . I don’t know whether it is short-term bottom reading or long-term optimistic about its future growth. Its position deserves attention.
last year, it made nearly 2 billion yuan in new profits, and the performance of its products was seriously divided
According to the data of China Fund Industry Association, the number of funds under management of Yingshui investment is as high as 419, the number of products is in the forefront of the whole industry, and the number of employees is 41.
It is worth noting that some people in the industry said that the main reason for the large number of Yingshui investment products is that in the past, Maotai Ping An and other stock bottom positions were used to make new ones, which brought obvious income enhancement to the fund, so they took advantage of the heat to issue new products. In 2020, Yingshui investment madly launched hundreds of products, and the scale exceeded the 10 billion mark in July of that year.
However, as a major player in the science and innovation board, Yingshui investment’s products have attracted much attention because they have been included in the “blacklist” of stock placement for two times.
On July 23, 2019, 18 private placement products under Yingshui investment, including “Yingshui Qihang No. 1 securities investment fund”, were also included in the “blacklist” of new share placement due to violations in the offline inquiry process of the first batch of new share issuance projects on the science and innovation board.
On May 8, 2020, due to irregularities in the offline subscription process of ” Hangzhou Raycloud Technology Co.Ltd(688365) ” and ” Greentech Environmental Co.Ltd(688466) ” new share issuance projects on the science and innovation board, the Securities Industry Association decided to include “Yingshui Feilong No. 1 private securities investment fund” under Yingshui investment in the restricted list of stock placement objects.
Although there were two violations, a total of 20 products were temporarily “black”, Yingshui investment was full of new profits.
According to the statistics of the securities market red weekly, nearly 400 products of Yingshui investment participated in 63521 IPO placements in 2021, second only to 66901 IPO placements of Lingjun investment (Lingjun hit a new floating profit of 2.147 billion yuan), plus seven fixed increases, the total allocation scale was 1.807 billion yuan, with a total floating profit of 2.248 billion yuan, that is, Yingshui investment only made a new profit of nearly 2 billion yuan in 2021.
However, with the frequent breaking of new shares this year, Yingshui investment, which relies on the new strategy, will also usher in the performance test.
It is worth noting that the Chinese reporter of the securities firm found that the performance of Yingshui investment’s products is seriously differentiated. Some of its products have achieved positive returns this year, some products are near the profit and loss, but many products have floating losses of more than 20%, and the net value of some products is even lower than 0.8.
It can also be seen from its position in the first quarter. As of April 28, a total of 39 products of Yingshui investment have been listed on the list of the top ten circulating shareholders of listed companies, with a total shareholding of 6.1 billion at the end of the period.
Some industry insiders said that the performance of private placement products varies greatly, which may make it difficult for investors to judge their real investment level, and the experience held by different customers will also vary greatly.
